24-months follow-up to assess the efficacy and tolerability of evolocumab in a young patient with chronic and progressive ischemic arteriopathy

Background and Aims: PCSK9 inhibitors represent a revolution for patients who do not reach their LDL-C target and need invasive and expensive treatments such as LDL-apheresis. We evaluated the efficacy and tolerability of evolocumab 140 mg Q2W during a follow-up period of 24 months in a 57-yo male patient with a history of early CHD (recurrent episodes of unstable angina and myocardial infarction treated with multiple PTCA+stent) and non-target LDL-C values despite maximum tolerated dose of lipid lowering therapy (LLT).